IFNA1 and hepatocellular carcinoma: Phenotypic substitutions at position 70 (change of arginine—wild type—to glutamine—mutant type—R70Q/H) and/or 91 (change of leucine or cysteine—wild type—to methionine—mutant type—L/C91M) of the core protein are associated with insulin resistance (IR), a more severe stage of liver disease for cirrhosis, HCC, and a non-sustained virological response to Peg-IFN-RBV combination therapy [10,11,12,13,14,15,16,17].